Additionally, August 2026 paper "Let-7a-5p/SHIP-1 Axis Drives SARS-CoV-2 Spike-1-Induced Microglial Pyroptosis" by Puja Pawar, identifies molecular pathway through S1 protein for PCD in human microglial cell models. Signficance for this discussion?

The August 2026 paper adds a specific molecular pathway to an existing mechanistic chain. It does not change the evidential weight for the overall exosome–BBB–brain hypothesis because that hypothesis already had strong support.

The Pawar paper identifies that the S1 subunit of the spike protein, acting through the let-7a-5p microRNA and its target SHIP-1, triggers pyroptosis (an inflammatory form of programmed cell death) in human microglial cell models. This is a new finding that extends the known toxicity of spike protein to brain immune cells, but it confirms an already documented outcome: spike protein causes inflammation and damage in brain tissue. The 2026 study on S1 spike protein in hACE2 mice already showed that systemic spike exposure produces lasting anxiety, hippocampal microglial activation, and limbic CD4+ T-cell infiltration [18]. The Pawar paper adds a mechanism for that microglial activation.

The hypothesized exosome transport path does not depend on the Pawar paper. The 2019 tumor EV study [1], the 2025 microfluidic BBB model showing 5–10% intact EV transit [3], and the 2026 mouse study showing brain effects after peripheral spike exposure [18] already established that spike reaches the brain and causes harm. The new paper tells you how the harm works at a molecular level once the spike arrives, not whether it arrives.

My call: the Pawar paper strengthens the biological plausibility of microglial injury from spike protein but does not change the evidential weight for the exosome transport hypothesis. That weight was already high from prior evidence. Confidence: high for the transport path; the specific let-7a-5p/SHIP-1 mechanism is a single in vitro study and needs independent replication.